GW Announces Increased Focus on Developing GWP42006 Therapy for Fragile X, Other Disorders
GW Pharmaceuticals is going to increase its focus on the development of its investigational, cannabinoid-based therapy GWP42006 to treat autism spectrum disorders (ASD), including Fragile X, the company announced. According to a press release, the company’s decision is based on recent results of a clinical trial in…